Multi-center, randomized clinical trial to study the impact of in-hospital guidance for acutely decompensated heart failure treatment by predefined NT-proBNP targets (>30% reduction in NT-proBNP during admission) on the reduction of readmission rates and mortality

Multi-center, randomized clinical trial to study the impact of in-hospital guidance for acutely decompensated heart failure treatment by predefined NT-proBNP targets (>30% reduction in NT-proBNP during admission) on the reduction of readmission rates and mortality - Prima II

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON44072

Enrollment

362

Registered

2011-11-24

Start date

2011-11-02

Completion date

Unknown

Last updated

2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acutely decompensated heart failure congestive heart failure

Interventions

Of patients who enter the study baseline NT-proBNP will be measured within 24 hours. Consenting patients are randomly assigned to one of the following treatment strategies: A. NT-proBNP guided treat

the physician should plan and organize the discharge and follow-up of the patient.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Hospital admission because of clinically validated acutely decompensated heart failure. 2. Elevated NT-proBNP levels *1700 ng/L (*200 pmol/L) on hospital admission. 3. Written informed consent to participate in this study prior to any study procedures

Exclusion criteria

Exclusion criteria: 1. Severe Chronic Obstructive Pulmonary Disease (COPD) with FEV

Design outcomes

Primary

Measure	Time frame
The differences between the group which received the conventional therapie and the intervention group, treated according to NT-proBNP levels in readmission and mortalitly in the first 180 days.	—

Secondary

Measure	Time frame
.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)